Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | SMO | Q99835 | 7/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.46 |
| ▸ | KHK | P50053 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363389 | 0.90 | CYP11B1 (0.69) | CYP11B1CYP11B2CCR1SMONR3C1 | |
| SCHEMBL347030 | 0.88 | TDP1 (0.49) | CYP11B1CYP11B2CCR1SMOKHK | |
| SCHEMBL1361914 | 0.82 | CYP11B1 (0.54) | CYP11B1CYP11B2CCR1SMONR3C1 | |
| SCHEMBL29810375 | 0.79 | CCR1 (0.52) | CYP11B1CYP11B2CCR1SMOPIK3CD | |
| SCHEMBL30614188 | 0.79 | BRD4 (0.51) | CYP11B1CYP11B2MAPK1 | |
| SCHEMBL25413272 | 0.79 | BRD4 (0.51) | CYP11B1CYP11B2MAPK1 | |
| SCHEMBL23449651 | 0.79 | CCR1 (0.52) | CYP11B1CYP11B2CCR1SMOPIK3CD | |
| SCHEMBL3666316 | 0.79 | CYP11B1 (0.54) | CYP11B1CYP11B2CCR1KHK | |
| SCHEMBL348090 | 0.78 | CYP11B1 (0.57) | CYP11B1CYP11B2SMONR3C1 | |
| SCHEMBL25412600 | 0.77 | KDM5A (0.43) | CYP11B1CYP11B2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330239-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330239-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3541374-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093696-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330239-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 | DGAT2, DGAT1, MOGAT2 | CYP11B1 312/4885CYP11B2 251/4885CCR1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.